|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cervical Cancer | |||||
| Precancerous/Nonmalignant Condition | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Carcinoma in Situ | |||||
| Cervical Intraepithelial Neoplasia | |||||
| Precancerous Conditions | |||||
| Uterine Cervical Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Carcinoma | |||||
| Genital Diseases, Female | |||||
| Genital Neoplasms, Female | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Urogenital Neoplasms | |||||
| Uterine Cervical Diseases | |||||
| Uterine Diseases | |||||
| Uterine Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| motexafin lutetium | |||||
| 5 | More general drug interventions related to this trial | ||||
| Dermatologic Agents | |||||
| Pharmacologic Actions | |||||
| Photosensitizing Agents | |||||
| Physiological Effects of Drugs | |||||
| Radiation-Sensitizing Agents | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| University of Pittsburgh | |||||
| National Cancer Institute (NCI) | |||||